Assessing the potential for precision medicine in body weight reduction with regard to type 2 diabetes mellitus therapies: A meta‐regression analysis of 120 randomized controlled trials
Authors' conclusion
We found no major treatment response heterogeneity in RCTs of glucose-lowering drugs for body weight reduction in type 2 diabetes. The precision medicine approach may thus be of limited value in this setting.
Study context
- Population
- Placebo-controlled randomized clinical trials (RCTs) of glucose-lowering drugs in T2D reporting body weight after treatment
- Participants
- 43,663 participants120 RCTs
- Comparison
- Glucose-lowering drugs vs placebo
- Primary endpoint
- Treatment response heterogeneity: variability of body weight after treatment (log[SD]) in verum vs placebo groups
Methodological detailsRCTs from four recent systematic reviews, placebo-controlled RCTs
- RCTs from four recent systematic reviews
- Placebo-controlled RCTs
Primary result
As reported in the abstract
Body weight log(SD) (treatment response heterogeneity)
Difference in body weight log(SD)
−0.026
95% CI −0.044 to 0.008
By group
Verum
2.83
median
Placebo
2.79
median
Verumvs Placebo
difference in body weight log(SD) −0.026 (95% CI −0.044 to 0.008)
Further findings
- Scatterplots showed no slope divergence (interaction) between clinical predictors and treatment (verum or placebo)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Assessing the potential for precision medicine in body weight reduction with regard to type 2 diabetes mellitus therapies: A meta‐regression analysis of 120 randomized controlled trials. Diabetes Obes Metab. Published 29 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →